The high-risk subgroup had a higher proportion of anti-inflammatory macrophage M2 cells, while the low-risk subgroup had an increased proportion of resting memory CD4 T cells, activated dendritic cells and mast cells, indicating the potential anti-tumor effects of the low-risk subgroup. This evidence concerns the gene CD4 and neoplasm.